Procyon

Procyon Technologies is a biotechnology company specializing in the development of advanced cellular therapies and delivery systems for chronic conditions, with a primary focus on Type 1 diabetes. The company’s core platform features oxygen-enabled implantable microchambers designed to protect and sustain transplanted cells, such as insulin-secreting islets, while mitigating foreign body responses and eliminating the need for systemic immunosuppression. Procyon has secured a high-profile exclusive research collaboration and license agreement with Novo Nordisk to integrate its encapsulation technology with stem cell-derived insulin-secreting cells. Additionally, the company is expanding its therapeutic reach into cardiovascular health through partnerships focused on heart repair using iPSC-derived mesenchymal stem cells. Headquartered in Tucson, Arizona, Procyon Technologies leverages innovations from the University of Arizona to address critical challenges in cell therapy viability and host integration.